［1］Brodeur GM，Azar C，Brother M，et al.Neuroblastoma.Effect of genetic factors on prognosis and treatment［J］.Cancer，1992，70(6 Suppl)：1685-1694.
［2］Brodeur GM，Iyer Radhika，Croucher JL，et al.Therapeutic targets for neuroblastomas［J］.Expert Opin Ther Targets，2014，18(3)：277-292.
［3］Davidoff AM.Neuroblastoma［J］.Semin Pediatr Surg，2012，21(1)：2-14.
［4］Armstrong JL，Martin S，Illingworth NA，et al.The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide［J］.Oncol Rep，2012，27(1)：293-298.
［5］Fabio M，Maria VC，Vito P.Evaluation of bone marrow as a metastatic site of human neuroblastoma［J］.Ann N Y Acad Sci，2015，1335：23-31.
［6］Fidler IJ.The pathogenesis of cancer metastasis：The'seed and soil' Hypothesis revisited［J］.Nat Rev Cancer，2003，3(06)：453-458.
［7］HaDuong JH，Blavier L，Baniwal SK，et al.Interaction between bone marrow stromal cells andneuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis［J］.2015，137(4)：797-809.
［8］Poretti A，Grotzer MA.Neuroblastoma with spinal cord compression：is there an emergency treatment of choice［J］?Dev Med Child Neurol，2012，54(4)：297-298.
［9］Sohara Y，Shimada H，DeClerck YA.Mechanisms of bone invasion and metastasis in human neuroblastoma［J］.Cancer Lett，2005，228(1-2)：203-209.
［10］Anderson DM，Maraskovsky E，Billingsley WL，et al.A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function［J］.Nature，1997，390(6656)：175-179.
［11］Simonet WS，Lacey DL，Dunstan CR，et al.Osteoprotegerin：a novel secreted protein involved in the regulation of bone density［J］.Cell，1997，89(02)：309-319.
［12］FN Song，M Duan，LZ Liu ，et al.RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB mediated epithelial-mesenchymal transition［J］.Plos One，2014，9(09)：e108507.
［13］Thomas RJ，Guise TA，Yin JJ，et al．Breast cancer cells interact with osteoclasts to support osteodasts formationl［J］.Endocrinology，1999，140(10)：4451-4458.
［14］Shin M，Matsuo K，Tada Takeyuki，et al.The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells［J］.Carcinogenesis，2011，32(11)：1634-1640.
［15］Liu Y，Wang J，Ni T，et al.CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells［J］.Oncotarget，2016，7（18）：25328-25339.
［16］González-Suárez Eva，Sanz-Moreno Adrián.Rank as a therapeutic target in cancer［J］.FEBS J，2016，283（11）：2018-2033.
［17］Lee ZH，Kim HH.Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts［J］.Biochem Biophys Res Commun，2003，305(2)：211-214.
［18］Li X，Jie Q，Zhang H，et al.Disturbed MEK/ERK signaling increases osteoclast activity via the Hedgehog-Gli pathway in postmenopausal osteoporosis［J］.Prog Biophys Mol Biol，2016，122（2）：101-111.
［19］Nie S，Xu J，Zhang CH，et al.Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways［J］.Biochem Biophys Res Commun，2016，470(1)：61-67.
［20］Lee K，Chung YH，Ahn H，et al.Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation.［J］.Int J Biol Sci，2016，12(2)：235-245.
［21］Novack DV.Role of NF-κB in the skeleton［J］.Cell Res，2011，21(1)：169-182.
［22］Chen Nong，Gao Rufeng，Yuan Fenglai，et al.Recombinant human endostatin suppresses mouse osteoclast formation by inhibiting the NF-κB and MAPKs signaling pathways［J］.Front Pharmacol，2016，7：145.
［23］Chen L，Huang M，Tan J，et al.PI3K/AKT pathway involvement in the osteogenic effects of osteoclast culture supernatants on preosteoblast cells［J］.Tissue Eng Part A，2013，19(19-20)：2226-2232.
［24］Moon JB，Kim JH，Kim K，et al.Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade［J］.J Immunol，2012，188(1)：163-169.
［25］Ara T，DeClerck YA.Mechanisms of invasion and metastasis in human neuroblastoma［J］.Cancer Metastasis Rev，2006，25：645-657.
［26］Zhao HY，Cai WS，Li S.Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines［J］.Childs Nerv Syst，2013，29：1097-1105.
［27］Zhao HY，Cai WS，Li S，et al.Establishment and characterization of xenograft models of human neuroblastoma bone metastasis.［J］.J China Medical University，2013，42：52-55.［赵红宇，蔡炜嵩，李帅，等.人类神经母细胞瘤骨转移模型的建立及鉴定［J］.中国医科大学学报，2013；42：52-55.］
［28］Sohara Y，Shimada H，Minkin Cedric，et al.Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells［J］.Cancer Research，2005，65(04)：1129-1135.
［29］Mitchell RA.Mechanisms and effectors of MIF-dependent promotion of tumourigenesis［J］.Cell Signal，2004，16(01)：13－19．
［30］Cage TA，Chanthery Y，Chesler L，et al.Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer［J］.Front Oncol，2015，5：111.
［31］Evans AE，Kisselbach KD，Liu X，et al.Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB［J］.Med Pediatr Oncol，2001，36(01)：181-184.